Ethacizine
![]() | |
| Clinical data | |
|---|---|
| Trade names | Ethacizin |
| AHFS/Drugs.com | International Drug Names |
| ATC code | C01BC09 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | ~40% (oral)[1] |
| Protein binding | 90% |
| Metabolism | Extensive hepatic |
| Biological half-life | 2.5 hours |
| Identifiers | |
| |
| CAS Number |
33414-33-4 |
| PubChem (CID) | 107841 |
| ChemSpider |
96982 |
| UNII |
FE5SPV1Z6G |
| ChEMBL |
CHEMBL1997663 |
| Chemical and physical data | |
| Formula | C22H27N3O3S |
| Molar mass | 413.54 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other CIS countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.[1]
It is manufactured under the brand name Ethacizin (Этацизин) by Olainfarm.[2]
References
- 1 2 "Этацизин (Ethacyzin) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 5 February 2014.
- ↑ "Этацизин—4DOKTOR.RU Drug Information Handbook" (in Russian). Retrieved 5 February 2014.
This article is issued from Wikipedia - version of the 5/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
